BMY Bristol Myers Squibb Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NYSE: BMY
  4. Earnings
?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 46
Relative Valuation: Rel. Valuation: 80
Relative Profitability: Rel. Profitability: 94

EPS in 2026 (TTM): $3.57

Last Report Period Date: Mar 31, 2026

According to the most recent financial data from March 2026, the current EPS (TTM) is $3.57. Bristol Myers Squibb's EPS for 2025 came in at $3.47, marking an increase from -$4.41 in 2024. For the quarterly period ending on Mar 31, 2026, BMY's EPS was $1.31.

BMY earnings history

Historical annual and quarterly earnings per share (EPS) data for Bristol Myers Squibb
EPS (TTM)
$3.57
EPS Growth YoY (Quarterly)
8.3%
EPS (Quarterly)
$1.31
EPS Growth (Quarterly)
142.6%

Bristol Myers Squibb had an annual EPS of $3.47, marking an increase of 178.7% from -$4.41 in 2024. The quarterly EPS for the period ending Mar 31, 2026, was $1.31, marking a 8.3% increase from the same quarter last year. BMY's TTM EPS stands at $3.57 as of March 2026. Bristol Myers Squibb's EPS for 2024 stood at -$4.41, a 213.7% decrease from 2023.

BMY earnings chart

BMY EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
8.3%
EPS growth YoY
178.7%
EPS growth 3Y avg
5.3%
EPS growth 5Y avg
N/A

Bristol Myers Squibb has recorded an increase in EPS of 8.3% over the last 12 months (YoY, quarterly). For the last three years, BMY recorded an average annual EPS growth rate of 5.3%. Across the last decade, BMY had an average annual EPS growth of 14%.

BMY Earnings Waterfall

Breakdown of revenue, profit and net income for Bristol Myers Squibb

BMY Earnings vs Peers

What are the earnings of BMY compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol Myers Squibb Co 15.41 178.7% 5.3% N/A
PFE Pfizer Inc 18.97 -3.5% -37.4% -3.7%
NVS Novartis AG 21.58 21.8% 31.2% 15.2%
AMGN Amgen Inc 23.89 88.1% 5.6% 2.9%
ABT Abbott Laboratories 24.61 -51.4% -1.8% 8.2%
AZN Astrazeneca plc 26.63 45.4% 46% 22%
JNJ Johnson & Johnson 26.87 90.6% 17.7% 14.8%
MRK Merck & Co Inc 32.61 8% 8.4% 21.2%
LLY ELI LILLY & Co 39.23 95.6% 49.2% 27.5%
ABBV AbbVie Inc 114.68 -1.3% -29.1% -2.8%

All data is based on quarterly TTM periods, unless otherwise specified.